SharpCell launches a plastic- and fossil-free material for premium napkins, with OrganoClicks biobased binder - Marketscreener.com
| ORGC Stock | SEK 2.82 0.01 0.35% |
Slightly above 62% of Organoclick's investor base is looking to short. The analysis of current outlook of investing in Organoclick AB suggests that many traders are alarmed regarding Organoclick's prospects. Organoclick's investing sentiment can be driven by a variety of factors including economic data, Organoclick's earnings reports, geopolitical events, and overall market trends.
Organoclick |
SharpCell launches a plastic- and fossil-free material for premium napkins, with OrganoClicks biobased binder Marketscreener.com
Read at news.google.com
 |
Organoclick Fundamental Analysis
We analyze Organoclick's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organoclick using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organoclick based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Organoclick is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Organoclick AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Organoclick stock to make a market-neutral strategy. Peer analysis of Organoclick could also be used in its relative valuation, which is a method of valuing Organoclick by comparing valuation metrics with similar companies.
Peers
Organoclick Related Equities
| LIPUM | Lipum AB | 6.43 | ||||
| MSON-A | Midsona AB | 3.48 | ||||
| NEXAM | Nexam Chemical | 2.10 | ||||
| KABE-B | KABE Group | 1.36 | ||||
| MEKO | Mekonomen | 0.15 | ||||
| ALBERT | EEducation Albert | 0.87 | ||||
| SALT-B | SaltX Technology | 1.04 | ||||
| AOI | Africa Oil | 1.59 | ||||
| IAR-B | IAR Systems | 2.02 | ||||
| CLS-B | Clinical Laserthermia | 2.82 |
Additional Tools for Organoclick Stock Analysis
When running Organoclick's price analysis, check to measure Organoclick's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organoclick is operating at the current time. Most of Organoclick's value examination focuses on studying past and present price action to predict the probability of Organoclick's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organoclick's price. Additionally, you may evaluate how the addition of Organoclick to your portfolios can decrease your overall portfolio volatility.